RAS pathway biomarkers for breast cancer prognosis.

Clinical laboratory international Pub Date : 2016-11-01
Lauren L Siewertsz van Reesema, Michael P Lee, Vasilena Zheleva, Janet S Winston, Caroline F O'Connor, Roger R Perry, Richard A Hoefer, Amy H Tang
{"title":"RAS pathway biomarkers for breast cancer prognosis.","authors":"Lauren L Siewertsz van Reesema,&nbsp;Michael P Lee,&nbsp;Vasilena Zheleva,&nbsp;Janet S Winston,&nbsp;Caroline F O'Connor,&nbsp;Roger R Perry,&nbsp;Richard A Hoefer,&nbsp;Amy H Tang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.</p>","PeriodicalId":91230,"journal":{"name":"Clinical laboratory international","volume":"40 ","pages":"18-23"},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455995/pdf/nihms866728.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory international","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Metastatic breast cancer is a highly heterogeneous, rapidly evolving and devastating disease that challenges our ability to find curative therapies. RAS pathway activation is an understudied research area in breast cancer. EGFR/RAS pathway activation is prevalent in breast cancer with poor prognosis. The prognostic RAS pathway biomarkers can be used to identify resistant tumour clones, stratify patients and guide therapies.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺癌预后的RAS通路生物标志物。
转移性乳腺癌是一种高度异质性、快速发展和毁灭性的疾病,对我们寻找治疗方法的能力提出了挑战。RAS通路激活在乳腺癌中是一个研究不足的研究领域。EGFR/RAS通路激活在预后不良的乳腺癌中普遍存在。预后RAS通路生物标志物可用于识别耐药肿瘤克隆,对患者进行分层并指导治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Point-of-Care Molecular Test for Zika Infection. RAS pathway biomarkers for breast cancer prognosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1